BANGALORE, India, March 24, 2022 /PRNewswire/ — The Antidepressant Drugs Market is Segmented by Product (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist Reuptake Inhibitors, and Others), Depressive Disorder (Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, and Others) The report covers global opportunity analysis, regional outlook, growth potential, industry forecast from 2021 to 2030.
The global antidepressant drugs market size was valued at USD 15,651.0 Million in 2020 and is projected to reach USD 21,004.8 Million by 2030, registering a CAGR of 3.0% from 2021 to 2030.
Major Factors Driving The Growth Of The Antidepressant Drugs Market
The increasing prevalence of life-threatening diseases such as depression, anxiety, and other mental health issues will drive the market growth. The need for better treatment access, growing government initiatives for increasing awareness, and covid 19 induced feelings of loneliness, social isolation will provide huge potential for the growth of the antidepressant drugs market.
Get your sample today: https://reports.valuates.com/request/sample/ALLI-Manu-1H67/Antidepressant_Drugs_Market
Trends Influencing The Growth Of The Antidepressant Drugs Market
Mental health issues such as obsessive-compulsive disorders, major depressive disorder, and other anxiety problems are on a rise globally. As per World Health Organization(WHO), about 5% of adults worldwide suffer from depression. Antidepressant drugs help by maintaining chemical balance in the brain, improve concentration, appetite, and help in sleeping better.
As per WHO nearly 40 Million people or 4.3% of the overall population in Europe suffer from depressive disorders. Furthermore, 3 out of 4 people across the world are suffering from depression. Moreover, according to the Centers for Disease Control and Prevention about 16 Million adults in America suffer from mental health conditions. The huge number of cases go unnoticed every year. Thus the need for enhanced treatment accessibility and a wide base of patients will create ample opportunities for the growth of the market in the coming years. . These figures suggest that the
Government authorities around the world are launching several programs aimed at increasing awareness levels and improving treatment methods. The favorable support facilities will further boost the antidepressant drugs market progression during the forecast period.
Covid 19 has significantly impacted the lives of millions of people around the world. As news regarding lockdowns, quarantine, and pressure on healthcare systems pile up, cases of mental health problems are also growing rapidly. Older adults, care providers, and people with comorbidities are scared and anxious. Feelings of stress, tension, loneliness, suicidal thinking, and depression have reached their peak. This, in turn, is expected to propel the growth of the antidepressant drugs market during the review period.
Browse The Table Of Contents And List Of Figures At: https://reports.valuates.com/reports/ALLI-Manu-1H67/antidepressant-drugs
Antidepressant Drugs Market Share Analysis
Based on product, the selective serotonin reuptake inhibitors segment dominated the antidepressant drugs market in 2020 and will continue to grow due to RD initiatives in the healthcare sector and the increasing prevalence of mental health disorders. On the other hand, the serotonin-norepinephrine reuptake inhibitors segment is expected to grow the fastest due to increasing cases of chronic nerve pain, and obsessive-compulsive disorder (OCD).
Based on depressive disorder, major depressive disorder was the dominant segment in 2020 and will continue growing during the forecast period, owing to the increase in the prevalence of major depressive disorder and initiatives taken by governments and private organizations about the development of drugs. However, the obsessive-compulsive disorder segment is expected to witness considerable growth during the forecast period, owing to an increase in the prevalence of mental disorders and an increase in the number of approval for anxiety drugs.
Based on region, North America dominated in 2020 and will continue to grow in the antidepressants market share due to the rising prevalence of depression cases, quick approval of antidepressants. RD initiatives and the presence of industry leaders. On the other hand, Asia-Pacific will grow at the fastest CAGR of 4.9% due to increasing awareness levels and rising healthcare infrastructure.
Inquire for Regional Data:
This report includes the following companies; we can also add the other companies as you want.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
H. Lundbeck A/S
Teva Pharmaceutical Industries Ltd. (Actavis Generics)
Takeda Pharmaceutical Limited Company
Buy Now for Single User + Covid-19 Impact : https://reports.valuates.com/api/directpaytoken?rcode=ALLI-Manu-1H67lic=single-user
We have introduced a tailor-made subscription for our customers. Please leave a note in the Comment Section to know about our subscription plans.
– The global Ibuprofen market size is estimated to be worth USD 96 Million in 2022 and is projected to reach USD 112.3 Million by 2028 with a CAGR of 2.7% during the forecast period.
– The global Antacids market size is estimated to be worth USD 6448.9 Million in 2022 and is projected to reach USD 7835.8 Million by 2028 with a CAGR of 3.3% during the forecast period.
– The U.S. pain management drugs market was valued at USD 31,499.07 Million in 2019, and is projected to reach USD 39,356.45 Million by 2027, registering a CAGR of 3.4%.
– The global pain management drugs market was valued at USD 71,431.85 Million in 2019, and is projected to reach USD 91,649.16 Million by 2027, registering a CAGR of 3.8%.
– The global Post-Traumatic Stress Disorder Therapeutics market size is projected to reach USD 3135.3 Million by 2028, from USD 2410.2 Million in 2021, at a CAGR of 3.8% during 2022-2028.
– The patient centric healthcare app accounted for USD 4,730 Million in 2019, and is expected to reach USD 64,331 Million by 2027, registering a CAGR of 37.2% from 2020 to 2027.
– The global Myotonic Dystrophy Drug market size is estimated to be worth USD 45 Million in 2022 and is forecast to a readjusted size of USD 67 Million by 2028 with a CAGR of 6.8% during the review period.
Valuates offers in-depth market insights into various industries. Our extensive report repository is constantly updated to meet your changing industry analysis needs.
Our team of market analysts can help you select the best report covering your industry. We understand your niche region-specific requirements and that’s why we offer customization of reports. With our customization in place, you can request for any particular information from a report that meets your market analysis needs.
To achieve a consistent view of the market, data is gathered from various primary and secondary sources, at each step, data triangulation methodologies are applied to reduce deviance and find a consistent view of the market. Each sample we share contains detail research methodology employed to generate the report, Please also reach to our sales team to get the complete list of our data sources
For U.S. Toll-Free Call +1-(315)-215-3225
For IST Call +91-8040957137
WhatsApp : +91 9945648335
Follow on Twitter – https://twitter.com/valuatesreports
Follow on Linkedin – https://in.linkedin.com/company/valuatesreports
Follow on Facebook – https://www.facebook.com/valuatesreports
SOURCE Valuates Reports